Status:
COMPLETED
Ropinirole Tablets In Young Patients With Restless Legs Syndrome
Lead Sponsor:
GlaxoSmithKline
Conditions:
Restless Legs Syndrome
Eligibility:
All Genders
12-17 years
Phase:
PHASE1
Brief Summary
This is a two-period dose rising study of Ropinirole Immediate Release in adolescent patients with restless legs syndrome (RLS) in order to determine the starting dose for the ropinirole titration reg...
Eligibility Criteria
Inclusion
- Adolescent subjects diagnosed with probable or definite Restless Leg Syndrome (RLS).
Exclusion
- Subjects who require RLS treatment during the daytime, suffer from other primary sleep disorders or are taking medication known to induce drowsiness, affect RLS or sleep, or to induce or treat alertness, including methylphenidate.
Key Trial Info
Start Date :
June 10 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2008
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00140712
Start Date
June 10 2005
End Date
February 28 2008
Last Update
September 11 2017
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Washington D.C., District of Columbia, United States, 20010
2
GSK Investigational Site
Macon, Georgia, United States, 31201
3
GSK Investigational Site
Chicago, Illinois, United States, 60611
4
GSK Investigational Site
Louisville, Kentucky, United States, 40202